Latest Pharming Grp Nv Leid (PHGUF) Headlines
Pharming Reports On Preliminary Financial Results 2013
Thomson Reuters ONE - Thu Mar 06, 12:00AM CST
- Revenues and other income decreased to EUR7.0 million (2012: EUR10.9 million) mainly as a result from lower license fees as 2012 included receipt of a EUR7.9 million milestone from our US partner Santarus for successful completion of study 1310 while 2013 included a EUR3.8 milestone from Santarus for acceptance for review of the BLA for Ruconest by the US FDA. Sales in 2013 increased to EUR0.9 million (2012: EUR0.8 million).
PHARMING AND SALIX ANNOUNCE EXTENSION OF PDUFA ACTION DATE FOR RUCONEST(r)
GlobeNewswire - Mon Feb 24, 12:12AM CST
Pharming Group NV (NYSE Euronext
HARM) and Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) today announced that the Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) Action Date to July 16, 2014 for the Company's Biologics License Application (BLA) for the investigational drug RUCONEST(R) (recombinant human C1 esterase inhibitor) 50 IU/kg. Pharming and Salix are seeking U.S. marketing approval of RUCONEST for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE).
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2013 Research Report
M2 - Thu Jan 23, 8:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/6c4qdd/fibrinogen) has announced the addition of the "Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2013" report to their offering. 'Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency). Scope - A snapshot of the global therapeutic scenario for Fibrinogen Deficiency (Factor I Deficiency). - A review of the Fibrinogen Deficiency (Factor I Deficiency) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Fibrinogen Deficiency (Factor I Deficiency) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Fibrinogen Deficiency (Factor I Deficiency). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Fibrinogen Deficiency (Factor I Deficiency) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Biotest AG Pharming Group N.V. Octapharma AG LFB S.A. China Biologic Products, Inc. For more information visit http://www.researchandmarkets.com/research/6c4qdd/fibrinogen About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Time for investors to move out of high-carbon assets, says UN climate change official
M2 - Thu Jan 16, 4:02AM CST
The top United Nations climate change official today urged investors to accelerate the greening of their portfolios as a crucial step towards a low-carbon economy that can better cope with the threats, and seize the opportunities from, climate change.
Market Research: Hereditary Angioedema (HAE) - Pipeline Review, H2 2013
M2 - Tue Dec 10, 2:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/x8rgxd/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) - Pipeline Review, H2 2013" report to their offering. 'Hereditary Angioedema (HAE) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hereditary Angioedema (HAE), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE). Scope - A snapshot of the global therapeutic scenario for Hereditary Angioedema (HAE). - A review of the Hereditary Angioedema (HAE) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hereditary Angioedema (HAE) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Isis Pharmaceuticals, Inc. Pharming Group N.V. Dyax Corp. ViroPharma Incorporated BioCryst Pharmaceuticals, Inc. CSL Limited iBio, Inc. For more information visit http://www.researchandmarkets.com/research/x8rgxd/hereditary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PHARMING AND SANTARUS ANNOUNCE NEW DATA FROM OPEN-LABEL REPEAT TREATMENT STUDY WITH RUCONEST
Thomson Reuters ONE - Fri Nov 08, 12:00AM CST
PHARMING AND SANTARUS ANNOUNCE NEW DATA FROM OPEN-LABEL REPEAT TREATMENT STUDY WITH RUCONEST (RECOMBINANT HUMAN C1 ESTERASE INHIBITOR)
Market Research: Ischemia Reperfusion Injury - Pipeline Review, H2 2013
M2 - Thu Nov 07, 2:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/zdcd6h/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H2 2013" report to their offering. 'Ischemia Reperfusion Injury - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ischemia Reperfusion Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury. Scope - A snapshot of the global therapeutic scenario for Ischemia Reperfusion Injury. - A review of the Ischemia Reperfusion Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ischemia Reperfusion Injury pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Pharming Group N.V. BioLineRx, Ltd. Proteo, Inc. Prolong Pharmaceuticals Trophos SA Curatis Pharma GmbH Alligator Bioscience AB Opsona Therapeutics Ltd. PledPharma AB Omeros Corporation Bolder Biotechnology, Inc. ADIENNE Pharma & Biotech Dr. Franz Kohler Chemie GmbH GENEXTRA S.p.A. ToleroTech Inc. Ischemix For more information visit http://www.researchandmarkets.com/research/zdcd6h/ischemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Pharming Reports On Financial Results For The First Nine Months Of 2013
Thomson Reuters ONE - Thu Nov 07, 12:00AM CST
PHARMING REPORTS ON FINANCIAL RESULTS FOR THE FIRST NINE MONTHS OF 2013
Kidney Transplantation - Pipeline Review, H2 2013
M2 - Mon Oct 14, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nn8sz9/kidney) has announced the addition of the "Kidney Transplantation - Pipeline Review, H2 2013" report to their offering. 'Kidney Transplantation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Kidney Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Transplantation. Scope - A snapshot of the global therapeutic scenario for Kidney Transplantation. - A review of the Kidney Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Kidney Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Kyowa Hakko Kirin Co., Ltd. GlaxoSmithKline plc Quark Pharmaceuticals, Inc. Pharming Group N.V. Isotechnika Pharma Inc. Astellas Pharma Inc. ViroPharma Incorporated 4SC AG LifeCycle Pharma A/S NPS Pharmaceuticals, Inc. La Jolla Pharmaceutical Company Alexion Pharmaceuticals, Inc. Portola Pharmaceuticals, Inc. Hansa Medical AB Digna Biotech, S.L. Viron Therapeutics, Inc. Opsona Therapeutics Ltd. Angion Biomedica Corp. NovImmune SA Tolera Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/nn8sz9/kidney About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Pharming announces EUR12.0 million private equity placement with institutional investors
Thomson Reuters ONE - Wed Oct 09, 12:00AM CDT
Leiden, the Netherlands, October 09, 2013. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it has entered into a private equity placement of EUR12.0 million (EUR11.5 million net proceeds after subtraction of transaction fees) with existing and new institutional investors. Participating institutional investors include current shareholders Deerfield Management Company, Kingdon Capital Management and Broadfin Capital.
Hemophilia - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rvbm6c/hemophilia) has announced the addition of the "Hemophilia - Pipeline Review, H2 2013" report to their offering. 'Hemophilia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia. Scope - A snapshot of the global therapeutic scenario for Hemophilia. - A review of the Hemophilia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemophilia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Baxter International Inc. Biogen Idec Inc. AstraZeneca PLC Nektar Therapeutics Cangene Corporation Lentigen Corporation Sangamo BioSciences, Inc. Pharming Group N.V. Novo Nordisk A/S BioMarin Pharmaceutical Inc. Chugai Pharmaceutical Co. Ltd Dong-A Pharmaceutical Co., Ltd. GTC Biotherapeutics, Inc. Octapharma AG Pain Therapeutics, Inc. Pfizer Inc. Bayer AG Living Cell Technologies Limited PROLOR Biotech, Inc. ReGenX Biosciences, LLC Alnylam Pharmaceuticals, Inc CSL Limited and many more... For more information visit http://www.researchandmarkets.com/research/rvbm6c/hemophilia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Hemophilia A - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Hemophilia
M2 - Wed Sep 04, 12:25PM CDT
Research and Markets (http://www.researchandmarkets.com/research/v3889m/hemophilia_a) has announced the addition of the "Hemophilia A - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Hemophilia A - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia A, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia A. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Hemophilia A. - A review of the Hemophilia A products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemophilia A pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Baxter International Inc. - Biogen Idec Inc. - AstraZeneca PLC - Cangene Corporation - Lentigen Corporation - Sangamo BioSciences, Inc. - Pharming Group N.V. - Novo Nordisk A/S - BioMarin Pharmaceutical Inc. - Dong-A Pharmaceutical Co., Ltd. - Octapharma AG - Pfizer Inc. - Bayer AG - PROLOR Biotech, Inc. - ReGenX Biosciences, LLC - Amarna Therapeutics B.V. - EpiVax, Inc. - Expression Therapeutics LLC - Asklepios BioPharmaceutical, Inc. - Amunix, Inc. - PolyTherics Limited - Celtic Pharmaceutical Holdings L.P. For more information visit http://www.researchandmarkets.com/research/v3...mophilia_a About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Transplantation - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2563g/transplantation) has announced the addition of the "Transplantation - Pipeline Review, H2 2013" report to their offering. 'Transplantation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Transplantation. Scope - A snapshot of the global therapeutic scenario for Transplantation. - A review of the Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Hospira, Inc. F. Hoffmann-La Roche Ltd. Kyowa Hakko Kirin Co., Ltd. Osiris Therapeutics, Inc. Athersys, Inc. GlaxoSmithKline plc Quark Pharmaceuticals, Inc. Merck & Co., Inc. AbGenomics International, Inc. Emergent BioSolutions Inc. Oxford BioMedica plc Pharming Group N.V. Vectura Group plc BioLineRx, Ltd. Novartis AG Isotechnika Pharma Inc. Samyang Corporation Astellas Pharma Inc. ViroPharma Incorporated Cell Therapeutics, Inc. Genmab A/S Exelixis, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/s2...plantation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Pharming Redeems Final Tranche of Convertible Bond for Cash
Marketwire - Thu Aug 29, 9:20AM CDT
Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it decided to redeem the seventh and final tranche of its EUR16.35 million convertible bond for cash. A total of EUR 2,354,465 will be paid in cash to the bondholders on 1 October 2013 under the terms and conditions of the bond, serving as a final redemption and interest payment.
Pharming redeems final tranche of convertible bond for cash
Thomson Reuters ONE - Thu Aug 29, 9:12AM CDT
No additional shares to be issued for final tranche
Pharming reports on financial results first half year 2013
Marketwire - Thu Aug 01, 12:10AM CDT
Leiden, The Netherlands, 1 August 2013. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today published its financial report for the six months ended 30 June 2013.
Pharming and Santarus announce poster presentation of pivotal clinical data for RUCONEST(R) (recombinant human C1 esterase inhibitor)
Marketwire - Tue Jun 25, 12:56AM CDT
Pharming Group NV (NYSE Euronext: PHARM) and Santarus, Inc. (NASDAQ: SNTS), announced that new data from a pivotal Phase III clinical study with RUCONEST(R) (recombinant human C1 esterase inhibitor) for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE) were featured in a poster presentation yesterday at the European Academy of Allergy and Clinical Immunology (EAACI) & World Allergy Organization (WAO) World Allergy & Asthma Congress in Milan, Italy. The data indicate that the time to beginning of relief of symptoms in patients experiencing an acute attack of HAE was statistically significantly shorter with RUCONEST compared with placebo.
Pharming and Santarus announce poster presentation of pivotal clinical data for RUCONEST® (recombinant human C1 esterase inhibitor)
Thomson Reuters ONE - Tue Jun 25, 12:00AM CDT
LEIDEN, Netherlands and SAN DIEGO (June 25, 2013) - Pharming Group NV (NYSE Euronext: PHARM) and Santarus, Inc. (NASDAQ: SNTS), announced that new data from a pivotal Phase III clinical study with RUCONEST® (recombinant human C1 esterase inhibitor) for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE) were featured in a poster presentation yesterday at the European Academy of Allergy and Clinical Immunology (EAACI) & World Allergy Organization (WAO) World Allergy & Asthma Congress in Milan, Italy. The data indicate that the time to beginning of relief of symptoms in patients experiencing an acute attack of HAE was statistically significantly shorter with RUCONEST compared with placebo.
Pharming Reports On Preliminary Financial Results 2013
Thomson Reuters ONE - Thu Mar 06, 12:00AM CST
- Revenues and other income decreased to EUR7.0 million (2012: EUR10.9 million) mainly as a result from lower license fees as 2012 included receipt of a EUR7.9 million milestone from our US partner Santarus for successful completion of study 1310 while 2013 included a EUR3.8 milestone from Santarus for acceptance for review of the BLA for Ruconest by the US FDA. Sales in 2013 increased to EUR0.9 million (2012: EUR0.8 million).
PHARMING AND SALIX ANNOUNCE EXTENSION OF PDUFA ACTION DATE FOR RUCONEST(r)
GlobeNewswire - Mon Feb 24, 12:12AM CST
Pharming Group NV (NYSE Euronext
HARM) and Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) today announced that the Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) Action Date to July 16, 2014 for the Company's Biologics License Application (BLA) for the investigational drug RUCONEST(R) (recombinant human C1 esterase inhibitor) 50 IU/kg. Pharming and Salix are seeking U.S. marketing approval of RUCONEST for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE). Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2013 Research Report
M2 - Thu Jan 23, 8:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/6c4qdd/fibrinogen) has announced the addition of the "Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2013" report to their offering. 'Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency). Scope - A snapshot of the global therapeutic scenario for Fibrinogen Deficiency (Factor I Deficiency). - A review of the Fibrinogen Deficiency (Factor I Deficiency) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Fibrinogen Deficiency (Factor I Deficiency) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Fibrinogen Deficiency (Factor I Deficiency). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Fibrinogen Deficiency (Factor I Deficiency) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Biotest AG Pharming Group N.V. Octapharma AG LFB S.A. China Biologic Products, Inc. For more information visit http://www.researchandmarkets.com/research/6c4qdd/fibrinogen About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Time for investors to move out of high-carbon assets, says UN climate change official
M2 - Thu Jan 16, 4:02AM CST
The top United Nations climate change official today urged investors to accelerate the greening of their portfolios as a crucial step towards a low-carbon economy that can better cope with the threats, and seize the opportunities from, climate change.
Market Research: Hereditary Angioedema (HAE) - Pipeline Review, H2 2013
M2 - Tue Dec 10, 2:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/x8rgxd/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) - Pipeline Review, H2 2013" report to their offering. 'Hereditary Angioedema (HAE) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hereditary Angioedema (HAE), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE). Scope - A snapshot of the global therapeutic scenario for Hereditary Angioedema (HAE). - A review of the Hereditary Angioedema (HAE) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hereditary Angioedema (HAE) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Isis Pharmaceuticals, Inc. Pharming Group N.V. Dyax Corp. ViroPharma Incorporated BioCryst Pharmaceuticals, Inc. CSL Limited iBio, Inc. For more information visit http://www.researchandmarkets.com/research/x8rgxd/hereditary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PHARMING AND SANTARUS ANNOUNCE NEW DATA FROM OPEN-LABEL REPEAT TREATMENT STUDY WITH RUCONEST
Thomson Reuters ONE - Fri Nov 08, 12:00AM CST
PHARMING AND SANTARUS ANNOUNCE NEW DATA FROM OPEN-LABEL REPEAT TREATMENT STUDY WITH RUCONEST (RECOMBINANT HUMAN C1 ESTERASE INHIBITOR)
Market Research: Ischemia Reperfusion Injury - Pipeline Review, H2 2013
M2 - Thu Nov 07, 2:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/zdcd6h/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H2 2013" report to their offering. 'Ischemia Reperfusion Injury - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ischemia Reperfusion Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury. Scope - A snapshot of the global therapeutic scenario for Ischemia Reperfusion Injury. - A review of the Ischemia Reperfusion Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ischemia Reperfusion Injury pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Pharming Group N.V. BioLineRx, Ltd. Proteo, Inc. Prolong Pharmaceuticals Trophos SA Curatis Pharma GmbH Alligator Bioscience AB Opsona Therapeutics Ltd. PledPharma AB Omeros Corporation Bolder Biotechnology, Inc. ADIENNE Pharma & Biotech Dr. Franz Kohler Chemie GmbH GENEXTRA S.p.A. ToleroTech Inc. Ischemix For more information visit http://www.researchandmarkets.com/research/zdcd6h/ischemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Pharming Reports On Financial Results For The First Nine Months Of 2013
Thomson Reuters ONE - Thu Nov 07, 12:00AM CST
PHARMING REPORTS ON FINANCIAL RESULTS FOR THE FIRST NINE MONTHS OF 2013
Kidney Transplantation - Pipeline Review, H2 2013
M2 - Mon Oct 14, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nn8sz9/kidney) has announced the addition of the "Kidney Transplantation - Pipeline Review, H2 2013" report to their offering. 'Kidney Transplantation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Kidney Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Transplantation. Scope - A snapshot of the global therapeutic scenario for Kidney Transplantation. - A review of the Kidney Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Kidney Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Kyowa Hakko Kirin Co., Ltd. GlaxoSmithKline plc Quark Pharmaceuticals, Inc. Pharming Group N.V. Isotechnika Pharma Inc. Astellas Pharma Inc. ViroPharma Incorporated 4SC AG LifeCycle Pharma A/S NPS Pharmaceuticals, Inc. La Jolla Pharmaceutical Company Alexion Pharmaceuticals, Inc. Portola Pharmaceuticals, Inc. Hansa Medical AB Digna Biotech, S.L. Viron Therapeutics, Inc. Opsona Therapeutics Ltd. Angion Biomedica Corp. NovImmune SA Tolera Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/nn8sz9/kidney About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Pharming announces EUR12.0 million private equity placement with institutional investors
Thomson Reuters ONE - Wed Oct 09, 12:00AM CDT
Leiden, the Netherlands, October 09, 2013. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it has entered into a private equity placement of EUR12.0 million (EUR11.5 million net proceeds after subtraction of transaction fees) with existing and new institutional investors. Participating institutional investors include current shareholders Deerfield Management Company, Kingdon Capital Management and Broadfin Capital.
Hemophilia - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rvbm6c/hemophilia) has announced the addition of the "Hemophilia - Pipeline Review, H2 2013" report to their offering. 'Hemophilia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia. Scope - A snapshot of the global therapeutic scenario for Hemophilia. - A review of the Hemophilia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemophilia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Baxter International Inc. Biogen Idec Inc. AstraZeneca PLC Nektar Therapeutics Cangene Corporation Lentigen Corporation Sangamo BioSciences, Inc. Pharming Group N.V. Novo Nordisk A/S BioMarin Pharmaceutical Inc. Chugai Pharmaceutical Co. Ltd Dong-A Pharmaceutical Co., Ltd. GTC Biotherapeutics, Inc. Octapharma AG Pain Therapeutics, Inc. Pfizer Inc. Bayer AG Living Cell Technologies Limited PROLOR Biotech, Inc. ReGenX Biosciences, LLC Alnylam Pharmaceuticals, Inc CSL Limited and many more... For more information visit http://www.researchandmarkets.com/research/rvbm6c/hemophilia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Hemophilia A - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Hemophilia
M2 - Wed Sep 04, 12:25PM CDT
Research and Markets (http://www.researchandmarkets.com/research/v3889m/hemophilia_a) has announced the addition of the "Hemophilia A - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Hemophilia A - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia A, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia A. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Hemophilia A. - A review of the Hemophilia A products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemophilia A pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Baxter International Inc. - Biogen Idec Inc. - AstraZeneca PLC - Cangene Corporation - Lentigen Corporation - Sangamo BioSciences, Inc. - Pharming Group N.V. - Novo Nordisk A/S - BioMarin Pharmaceutical Inc. - Dong-A Pharmaceutical Co., Ltd. - Octapharma AG - Pfizer Inc. - Bayer AG - PROLOR Biotech, Inc. - ReGenX Biosciences, LLC - Amarna Therapeutics B.V. - EpiVax, Inc. - Expression Therapeutics LLC - Asklepios BioPharmaceutical, Inc. - Amunix, Inc. - PolyTherics Limited - Celtic Pharmaceutical Holdings L.P. For more information visit http://www.researchandmarkets.com/research/v3...mophilia_a About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Transplantation - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2563g/transplantation) has announced the addition of the "Transplantation - Pipeline Review, H2 2013" report to their offering. 'Transplantation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Transplantation. Scope - A snapshot of the global therapeutic scenario for Transplantation. - A review of the Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Hospira, Inc. F. Hoffmann-La Roche Ltd. Kyowa Hakko Kirin Co., Ltd. Osiris Therapeutics, Inc. Athersys, Inc. GlaxoSmithKline plc Quark Pharmaceuticals, Inc. Merck & Co., Inc. AbGenomics International, Inc. Emergent BioSolutions Inc. Oxford BioMedica plc Pharming Group N.V. Vectura Group plc BioLineRx, Ltd. Novartis AG Isotechnika Pharma Inc. Samyang Corporation Astellas Pharma Inc. ViroPharma Incorporated Cell Therapeutics, Inc. Genmab A/S Exelixis, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/s2...plantation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Pharming Redeems Final Tranche of Convertible Bond for Cash
Marketwire - Thu Aug 29, 9:20AM CDT
Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it decided to redeem the seventh and final tranche of its EUR16.35 million convertible bond for cash. A total of EUR 2,354,465 will be paid in cash to the bondholders on 1 October 2013 under the terms and conditions of the bond, serving as a final redemption and interest payment.
Pharming redeems final tranche of convertible bond for cash
Thomson Reuters ONE - Thu Aug 29, 9:12AM CDT
No additional shares to be issued for final tranche
Pharming reports on financial results first half year 2013
Marketwire - Thu Aug 01, 12:10AM CDT
Leiden, The Netherlands, 1 August 2013. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today published its financial report for the six months ended 30 June 2013.
Pharming and Santarus announce poster presentation of pivotal clinical data for RUCONEST(R) (recombinant human C1 esterase inhibitor)
Marketwire - Tue Jun 25, 12:56AM CDT
Pharming Group NV (NYSE Euronext: PHARM) and Santarus, Inc. (NASDAQ: SNTS), announced that new data from a pivotal Phase III clinical study with RUCONEST(R) (recombinant human C1 esterase inhibitor) for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE) were featured in a poster presentation yesterday at the European Academy of Allergy and Clinical Immunology (EAACI) & World Allergy Organization (WAO) World Allergy & Asthma Congress in Milan, Italy. The data indicate that the time to beginning of relief of symptoms in patients experiencing an acute attack of HAE was statistically significantly shorter with RUCONEST compared with placebo.
Pharming and Santarus announce poster presentation of pivotal clinical data for RUCONEST® (recombinant human C1 esterase inhibitor)
Thomson Reuters ONE - Tue Jun 25, 12:00AM CDT
LEIDEN, Netherlands and SAN DIEGO (June 25, 2013) - Pharming Group NV (NYSE Euronext: PHARM) and Santarus, Inc. (NASDAQ: SNTS), announced that new data from a pivotal Phase III clinical study with RUCONEST® (recombinant human C1 esterase inhibitor) for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE) were featured in a poster presentation yesterday at the European Academy of Allergy and Clinical Immunology (EAACI) & World Allergy Organization (WAO) World Allergy & Asthma Congress in Milan, Italy. The data indicate that the time to beginning of relief of symptoms in patients experiencing an acute attack of HAE was statistically significantly shorter with RUCONEST compared with placebo.
